Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.60 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.60 |
| ▸ | TST | Q16762 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 9/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874725 | 1.00 | MAPT (0.60) | MAPTHSPD1HSPE1TSTRECQL | |
| SCHEMBL15364 | 1.00 | MAPT (0.60) | MAPTHSPD1HSPE1TSTRECQL | |
| SCHEMBL16950234 | 1.00 | MAPT (0.60) | MAPTHSPD1HSPE1TSTRECQL | |
| SCHEMBL875292 | 1.00 | MAPT (0.60) | MAPTHSPD1HSPE1TSTRECQL | |
| SCHEMBL444603 | 1.00 | MAPT (0.60) | MAPTHSPD1HSPE1TSTRECQL | |
| SCHEMBL1503121 | 1.00 | MAPT (0.60) | MAPTHSPD1HSPE1TSTRECQL | |
| SCHEMBL16201 | 1.00 | MAPT (0.60) | MAPTHSPD1HSPE1TSTRECQL | |
| SCHEMBL875399 | 1.00 | MAPT (0.60) | MAPTHSPD1HSPE1TSTRECQL | |
| SCHEMBL22730055 | 1.00 | MAPT (0.60) | MAPTHSPD1HSPE1TSTRECQL | |
| SCHEMBL875356 | 1.00 | MAPT (0.60) | MAPTHSPD1HSPE1TSTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3506907-B1 | COMBINATION CANCER THERAPY WITH A PENTAAZA MACROCYCLIC RING COMPLEX AND AN ASCORBATE COMPOUND | GALERA LABS LLC (US) | 2023-06-07 | — | — | EP | claimed |
| US-20230165929-A1 | TREATMENT OF RESPIRATORY TRACT DISEASES AND INFECTIONS WITH ASCORBIC ACID COMPOSITIONS | RENOVION, INC. | 2023-06-01 | — | — | US | claimed |
| US-20220304977-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND ASCORBATE COMPOUND | BIOSSIL INC. (CA) | 2022-09-29 | — | — | US | claimed |
| US-11219614-B2 | Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound | GALERA LABS, LLC (US) | 2022-01-11 | — | — | US | claimed |
| US-20190351005-A1 | TREATMENT OF RESPIRATORY TRACT DISEASES AND INFECTIONS WITH ASCORBIC ACID COMPOSITIONS | RENOVION, INC. | 2019-11-21 | — | — | US | claimed |
| EP-3541401-A1 | TREATMENT OF RESPIRATORY TRACT DISEASES AND INFECTIONS WITH GLUTATHIONE COMPOSITIONS | Renovion, Inc. (US) | 2019-09-25 | — | — | EP | claimed |
| US-20190209524-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND ASCORBATE COMPOUND | BIOSSIL INC. (CA) | 2019-07-11 | — | — | US | claimed |
| EP-3506907-A2 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND ASCORBATE COMPOUND | Galera Labs, LLC (US) | 2019-07-10 | — | — | EP | claimed |
| WO-2018094278-A1 | TREATMENT OF RESPIRATORY TRACT DISEASES AND INFECTIONS WITH GLUTATHIONE COMPOSITIONS | RENOVION, INC. (US) | 2018-05-24 | — | — | WO | claimed |
| US-9649283-B2 | Treatment of urinary incontinence using nitrone spin traps | PERRICONE NICHOLAS V (US) | 2017-05-16 | — | — | US | claimed |
| WO-2009046033-A2 | SILICONE GEL-BASED COMPOSITIONS FOR WOUND HEALING AND SCAR REDUCTION | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2009-04-09 | — | — | WO | claimed |
| EP-0944310-B8 | STABILIZED ASCORBYL COMPOSITIONS | PERRICONE NICHOLAS V DR (US) | 2005-06-01 | — | — | EP | claimed |
| EP-0944310-B1 | STABILIZED ASCORBYL COMPOSITIONS | PERRICONE NICHOLAS V DR (US) | 2005-04-06 | — | — | EP | claimed |
| WO-2001082878-A1 | TREATMENT OF SKIN DAMAGE USING ACETYL CARNITINE AND PHOSPHATIDYLCHOLINE AND/OR ASCORBYL FATTY ACID ESTERS | PERRICONE NICHOLAS V (US) | 2001-11-08 | — | — | WO | claimed |
| WO-2001082861-A2 | TREATMENT OF SKIN DAMAGE USING CONJUGATED LINOLEIC ACID AND ASCORBYL FATTY ACID ESTERS | PERRICONE NICHOLAS V (US) | 2001-11-08 | — | — | WO | claimed |
| US-6296861-B1 | Treatment of skin damage using conjugated linoleic acid and ascorbyl fatty acid esters | THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY, AS ADMINISTRATIVE AGENT | 2001-10-02 | — | — | US | claimed |
| EP-0944310-A4 | STABILIZED ASCORBYL COMPOSITIONS | PERRICONE NICHOLAS V DR (US) | 2001-01-10 | — | — | EP | claimed |
| US-6162419-A | Stabilized ascorbyl compositions | Perricone, Nicholas V. (US) | 2000-12-19 | — | — | US | claimed |
| EP-0944310-A1 | STABILIZED ASCORBYL COMPOSITIONS | PERRICONE, Nicholas V., Dr. (US) | 1999-09-29 | — | — | EP | claimed |
| WO-1998023152-A1 | STABILIZED ASCORBYL COMPOSITIONS | PERRICONE NICHOLAS V (US) | 1998-06-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220304977-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND ASCORBATE COMPOUND | FOLR1, SLC19A1, FOLR2 | MAPT 3683/4885HSPD1 1336/4885HSPE1 905/4885 |
| US-20230165929-A1 | TREATMENT OF RESPIRATORY TRACT DISEASES AND INFECTIONS WITH ASCORBIC ACID COMPOSITIONS | GPX1, GPX4, GSR | MAPT 2926/4885HSPD1 456/4885HSPE1 318/4885 |
| US-11219614-B2 | Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound | FOLR1, SLC19A1, FOLR2 | MAPT 3683/4885HSPD1 1336/4885HSPE1 905/4885 |
| US-20190351005-A1 | TREATMENT OF RESPIRATORY TRACT DISEASES AND INFECTIONS WITH ASCORBIC ACID COMPOSITIONS | GPX1, GPX4, GSR | MAPT 2926/4885HSPD1 456/4885HSPE1 318/4885 |
| US-20190209524-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND ASCORBATE COMPOUND | FOLR1, SLC19A1, FOLR2 | MAPT 3683/4885HSPD1 1336/4885HSPE1 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.